Myriad Strengthens Commitment to Cancer Research at the ASCO 50th Annual Meeting
May 15 2014 - 7:05AM
Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that results
from 11 clinical studies with its molecular diagnostic tests will
be featured at the 2014 American Society of Clinical Oncology
annual meeting to be held May 30-June 3, 2014 in Chicago, Ill.
Abstracts of the Company's presentations are available at:
abstracts.asco.org.
The molecular diagnostic tests being highlighted at ASCO address
four key areas of focus for Myriad including hereditary cancer,
melanoma, companion diagnostics and prostate cancer. There will be
presentations on six new key studies on the Myriad myRisk™
Hereditary Cancer test, including two podium presentations; two
presentations on the Myriad myPath™ Melanoma test, including the
first pivotal clinical validation study; and the presentation of
new clinical data on the HRD companion diagnostic in patients with
metastatic triple negative breast cancer.
"Myriad is committed to advancing all aspects of cancer care –
risk assessment, diagnosis, prognosis and treatment selection – and
has a robust portfolio and pipeline of molecular and companion
diagnostics," said Mark Capone, president of Myriad Genetics
Laboratories. "We believe much more can be done through
diagnostics to improve patient care and lower health care costs.
Through our strong internal and external research programs, Myriad
is leading the discovery, development and commercialization of the
next generation of diagnostic tests and services."
The list of key Myriad presentations follows.
Myriad myRisk
Hereditary Cancer Testing |
|
Title: |
A study of ovarian cancer patients tested
with a 25-gene panel of hereditary cancer genes. |
Presenter: |
Lucy Langer |
Date: |
Monday, June 2, 8:48 a.m. - 9:00 a.m. (Podium
Presentation; Location S100a) |
|
|
Title: |
Multigene panel testing in patients suspected
to have Lynch syndrome. |
Presenter: |
Matthew Yurgelun |
Date: |
Monday, June 2, 8:00 a.m. - 8:12 a.m. (Podium
Presentation; Location S100a) |
|
|
Title: |
Analysis of patients with two hereditary
cancers (breast/ovarian or colon/endometrial) who met NCCN genetic
testing criteria after their first cancer. |
Presenter: |
Jennifer Saam |
Date: |
Sunday, June 1, 8:00 a.m. - 11:45 a.m.
(Poster 1542) |
|
|
Title: |
Impact of 25-gene panel testing and
integrated risk management tool on medical management in hereditary
cancer syndrome evaluation. |
Presenter: |
Lee Schwartzberg |
Date: |
Sunday, June 1, 8:00 a.m. - 11:45 a.m.
(Poster 1553) |
|
|
Title: |
The clinical experience: Hereditary cancer
testing by a 25-gene panel. |
Presenter: |
Elias Obeid |
Date: |
Sunday, June 1, 8:00 a.m. - 11:45 a.m.
(Poster 1548) |
|
|
Title: |
Evaluation of breast cancer incidence in
Lynch syndrome patients by MMR gene. |
Presenter: |
Jamie Willmott |
Date: |
Sunday, June 1, 8:00 a.m. - 11:45 a.m.
(Poster 1541) |
|
|
Myriad myPath
Melanoma |
|
Title: |
Development and validation of a gene
expression signature to distinguish malignant melanoma from benign
nevi. |
Presenter: |
Colleen Rock |
Date: |
Monday, June 2, 8:00 a.m. - 12:00 p.m.;
Discussion 11:30 a.m. – 12:45 p.m. (Highlighted Poster 9021) |
|
|
Title: |
The influence of a gene expression signature
on the diagnosis and recommended treatment of melanocytic tumors by
dermatopathologists. |
Presenter: |
Loren Clarke |
Date: |
Saturday, May 31, 8:00 a.m. - 11:45 a.m.
(Poster TPS9111) |
|
|
HRD
(Companion Diagnostic) |
|
Title: |
Identification of biomarkers to predict
response to single-agent platinum chemotherapy in metastatic triple
negative breast cancer (mTNBC): Correlative studies from
TBCRC009. |
Presenter: |
Steven Isakoff |
Date: |
Tuesday, June 3, 9:45 a.m. - 12:45 p.m.
(Podium Presentation; Location E Hall D1) |
|
|
Title: |
TBCRC030: A randomized phase II study of
preoperative cisplatin versus paclitaxel in patients (pts) with
BRCA1/2-proficient triple negative breast cancer (TNBC): Evaluating
the Homologous Recombination Deficiency (HRD) Biomarker |
Presenter: |
Erica Mayer |
Date: |
Monday, June 2, 8:00 a.m. - 11:45 a.m.
(Poster TPS1445) |
|
|
Prolaris |
|
Title: |
Validation of an RNA cell cycle progression
(CCP) score for predicting prostate cancer death in a
conservatively managed needle biopsy cohort |
Presenter: |
Jack Cuzick |
Date: |
Monday, June 2, 1:15 p.m. - 5:00 p.m. (Poster
5059) |
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic company
dedicated to making a difference in patients' lives through the
discovery and commercialization of transformative tests to assess a
person's risk of developing disease, guide treatment decisions and
assess risk of disease progression and recurrence. Myriad's
molecular diagnostic tests are based on an understanding of the
role genes play in human disease and were developed with a
commitment to improving an individual's decision making process for
monitoring and treating disease. Myriad is focused on strategic
directives to introduce new products, including companion
diagnostics, as well as expanding internationally. For more
information on how Myriad is making a difference, please visit the
Company's website: www.myriad.com.
Myriad, the Myriad logo, Prolaris, Myriad myPath, Myriad myPlan,
and Myriad myRisk are trademarks or registered trademarks of Myriad
Genetics, Inc. in the United States and foreign countries. MYGN-F,
MYGN-G.
Safe Harbor Statement
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the dates, times and
presentation of clinical study data at the 2014 ASCO Annual
Meeting; and the Company's strategic directives under the caption
"About Myriad Genetics." These "forward-looking statements"
are management's present expectations of future events and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those
described in the forward-looking statements. These risks
include, but are not limited to: the risk that sales and profit
margins of our existing molecular diagnostic tests and companion
diagnostic services may decline or will not continue to increase at
historical rates; risks related to changes in the governmental or
private insurers reimbursement levels for our tests; the risk that
we may be unable to develop or achieve commercial success for
additional molecular diagnostic tests and companion diagnostic
services in a timely manner, or at all; the risk that we may not
successfully develop new markets for our molecular diagnostic tests
and companion diagnostic services, including our ability to
successfully generate revenue outside the United States; the risk
that licenses to the technology underlying our molecular diagnostic
tests and companion diagnostic services tests and any future tests
are terminated or cannot be maintained on satisfactory terms; risks
related to delays or other problems with operating our laboratory
testing facilities; risks related to public concern over our
genetic testing in general or our tests in particular; risks
related to regulatory requirements or enforcement in the United
States and foreign countries and changes in the structure of the
healthcare system or healthcare payment systems; risks related to
our ability to obtain new corporate collaborations or licenses and
acquire new technologies or businesses on satisfactory terms, if at
all; risks related to our ability to successfully integrate and
derive benefits from any technologies or businesses that we license
or acquire; risks related to increased competition and the
development of new competing tests and services; the risk that we
or our licensors may be unable to protect or that third parties
will infringe the proprietary technologies underlying our tests;
the risk of patent-infringement claims or challenges to the
validity of our patents; risks related to changes in intellectual
property laws covering our molecular diagnostic tests and companion
diagnostic services and patents or enforcement in the United States
and foreign countries, such as the Supreme Court decision in the
lawsuit brought against us by the Association for Molecular
Pathology et al; risks of new, changing and competitive
technologies and regulations in the United States and
internationally; and other factors discussed under the heading
"Risk Factors" contained in Item 1A of our most recent Annual
Report on Form 10-K filed with the Securities and Exchange
Commission, as well as any updates to those risk factors filed from
time to time in our Quarterly Reports on Form 10-Q or Current
Reports on Form 8-K. All information in this press release is as of
the date of the release, and Myriad undertakes no duty to update
this information unless required by law.
CONTACT: Media Contact:
Ron Rogers
(801) 584-3065
rrogers@myriad.com
Investor Contact:
Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024